COLL · Nasdaq · CIK 0001267565
COLLEGIUM PHARMACEUTICAL, INC
COLLEGIUM PHARMACEUTICAL, INC’s most recent SEC filing in our snapshot is a Form 8-K filed on Oct 19, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $780.6M and net income of $62.9M, according to its XBRL data on EDGAR. Its EDGAR record lists 25 Form 4 insider filings from the 12 months before our last refresh.
SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.
Company overview
- Legal name (as filed)
- COLLEGIUM PHARMACEUTICAL, INC
- Ticker
- COLL
- SEC Central Index Key (CIK)
- 0001267565
- Industry (SIC)
- Pharmaceutical Preparations (code 2834)
- Business address
- STOUGHTON, MA
- State or country of incorporation
- VA
- Fiscal year ends
- December 31
- SEC filer category
- Large accelerated filer
- Position in SEC ticker list
- #2598 of the 3,000 companies we track
Five-year financial highlights
Full-year figures from COLLEGIUM PHARMACEUTICAL, INC’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.
| Item | FY2021 ended Dec 31, 2021 | FY2022 ended Dec 31, 2022 | FY2023 ended Dec 31, 2023 | FY2024 ended Dec 31, 2024 | FY2025 ended Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $276.9M | $463.9M | $566.8M | $631.4M | $780.6M |
| Net income | $71.5M | -$25.0M | $48.2M | $69.2M | $62.9M |
| Diluted EPS | $1.86 | -$0.74 | $1.29 | $1.86 | $1.73 |
| Total assets | $692.1M | $1.2B | $1.1B | $1.7B | $1.7B |
| Cash and equivalents | $186.4M | $173.7M | $238.9M | $70.6M | $231.3M |
XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.
How to read these numbers
Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.
Advertisement
Latest key reports
The most recent filing of each major report type, even if it falls outside the 40 newest filings below.
| Filed | Form | What it is | Original |
|---|---|---|---|
| Feb 26, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Aug 6, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Oct 19, 2026 | 8-K | Agreement terminated· period Oct 15, 2026 | Document · Index |
| Apr 7, 2026 | DEF 14A | Definitive proxy statement· period May 14, 2026 | Document · Index |
Recent SEC filings
The 40 newest documents filed by or about COLLEGIUM PHARMACEUTICAL, INC, by form type:
| Filed | Form | What it is | Original |
|---|---|---|---|
| Oct 19, 2026 | 8-K | Agreement terminated· period Oct 15, 2026 | Document · Index |
| Oct 8, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Sep 30, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Aug 24, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| Aug 14, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| Aug 13, 2026 | 8-K | Other events· period Aug 12, 2026 | Document · Index |
| Aug 6, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Aug 6, 2026 | 8-K | Results of operations; Regulation FD disclosure· period Aug 6, 2026 | Document · Index |
| Aug 5, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| Jul 31, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| Jul 17, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Jul 15, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Jun 30, 2026 | 8-K/A | Current report· period May 12, 2026 | Document · Index |
| Jun 10, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 8, 2026 | Document · Index |
| Jun 1, 2026 | S-8 | Registration of employee benefit plan securities | Document · Index |
| Jun 1, 2026 | S-8 | Registration of employee benefit plan securities | Document · Index |
| May 20, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 18, 2026 | Document · Index |
| May 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 14, 2026 | Document · Index |
| May 18, 2026 | 3 | Initial statement of beneficial ownership· period May 14, 2026 | Document · Index |
| May 18, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| May 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 14, 2026 | Document · Index |
| May 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 14, 2026 | Document · Index |
| May 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 14, 2026 | Document · Index |
| May 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 14, 2026 | Document · Index |
| May 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 14, 2026 | Document · Index |
| May 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 14, 2026 | Document · Index |
| May 15, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| May 15, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| May 15, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 13, 2026 | Document · Index |
| May 15, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| May 15, 2026 | 8-K | Shareholder vote results· period May 14, 2026 | Document · Index |
| May 14, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| May 13, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| May 13, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 11, 2026 | Document · Index |
| May 12, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| May 12, 2026 | 8-K | Acquisition or disposition completed; Director or officer change; Regulation FD disclosure· period May 12, 2026 | Document · Index |
| May 11, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| May 8, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| May 7, 2026 | 10-Q | Quarterly report· period Mar 31, 2026 | Document · Index |
| May 7, 2026 | 8-K | Results of operations; Regulation FD disclosure· period May 7, 2026 | Document · Index |
Insider filing activity
25 Form 4 filings appear in COLLEGIUM PHARMACEUTICAL, INC’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.
Advertisement
Other companies in Pharmaceutical Preparations
- LLY ELI LILLY & Co
- JNJ JOHNSON & JOHNSON
- ABBV AbbVie Inc.
- MRK Merck & Co., Inc.
- NVS NOVARTIS AG
- AZN ASTRAZENECA PLC
- ABT ABBOTT LABORATORIES
- NVO NOVO NORDISK A S
All 194 companies in Pharmaceutical Preparations· Companies headquartered in Massachusetts
On Amazon
Popular tools for investors
As an Amazon Associate I earn from qualifying purchases.
Source
- U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001267565 and XBRL company facts. COLLEGIUM PHARMACEUTICAL, INC on EDGAR.
- Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.
Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.
Advertisement